IRB approval from TASMC follows Clearmind’s prior regulatory milestones, including U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application and IRB approvals ...

The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

AI Code of Conduct’s six core principles key to ensuring the safe and effective use of AI technologies ...

The Foundation has been awarded the Gold Seal for Transparency by Guidestar for eight consecutive years. Your contributions support its mission to defend taxpayers and cancer patients by advocating ...

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are ...

On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to employees and board ...

Oxford BioTherapeutics is a clinical stage oncology company discovering and developing first in class antibody-based therapies designed to fulfil major unmet patient needs in cancer therapy. These ...

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, August 7, ...

Egham, UK – 03 July 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the ...

L-Leucine (amount not specified): An essential amino acid, L-leucine helps preserve lean muscle mass during weight loss, ...

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis ...

Une offre de 3,01 $ US en espèces plus un droit conditionnel à la valeur représentant des paiements supplémentaires totaux potentiels pouvant atteindre 1,19 $ US par action La contrepartie initiale et ...